Lapatinib Ditosylate

Breast, Advance Directives, Postmenopause + 1 more
Treatment
6 FDA approvals
8 Active Studies for Lapatinib Ditosylate

What is Lapatinib Ditosylate

LapatinibThe Generic name of this drug
Treatment SummaryLapatinib is an anti-cancer medication developed by GlaxoSmithKline (GSK) to treat solid tumors such as breast and lung cancer. It was approved by the FDA in 2007 and is used in combination with the chemotherapy drug Capecitabine. Lapatinib works by blocking the activity of two proteins in the body, HER2/ERBB2 and HER1/EGFR/ERBB1. This prevents them from binding together, which helps stop the growth and spread of cancer cells.
Tykerbis the brand name
image of different drug pills on a surface
Lapatinib Ditosylate Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tykerb
Lapatinib
2007
3

Approved as Treatment by the FDA

Lapatinib, also called Tykerb, is approved by the FDA for 6 uses which include refractory, metastatic Breast cancer and Metastatic Breast Cancer .
refractory, metastatic Breast cancer
Used to treat refractory, metastatic Breast cancer in combination with Capecitabine
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Letrozole
Breast
Used to treat refractory, metastatic Breast cancer in combination with Capecitabine
Postmenopause
Used to treat Postmenopausal in combination with Letrozole
Advance Directives
Used to treat refractory, advanced Breast cancer in combination with Capecitabine
Metastatic Breast Cancer
Used to treat Metastatic Breast Cancer in combination with Letrozole

Effectiveness

How Lapatinib Ditosylate Affects PatientsLapatinib is a medication used to treat certain types of cancer, such as breast and lung cancer. It inhibits the growth of cancer cells by blocking certain proteins known as kinases. Developed by GlaxoSmithKline, the FDA approved lapatinib for use in advanced metastatic breast cancer in combination with capecitabine chemotherapy on March 13, 2007.
How Lapatinib Ditosylate works in the bodyLapatinib is a drug that works to stop cancer cells from growing. It works by targeting the tyrosine kinase domains of the epidermal growth factor receptor and human epidermal growth factor receptor, which are both associated with cancer. Studies have shown that Lapatinib is effective in stopping tumor cell growth in laboratory and animal models, and that it can be used in combination with other cancer medications for an even greater effect. Lapatinib also works well against cancer cells that have become resistant to other treatments.

When to interrupt dosage

The suggested amount of Lapatinib Ditosylate is contingent upon the recognized disorder, including Advance Directives, Postmenopause and Metastatic Breast Cancer. The quantity of dosage shifts, as per the approach of administration (e.g. Tablet - Oral or Oral) featured in the table beneath.
Condition
Dosage
Administration
Breast
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Advance Directives
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Postmenopause
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral
Metastatic Breast Cancer
, 250.0 mg
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Lapatinib Ditosylate.
Common Lapatinib Ditosylate Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The serum concentration of Abemaciclib can be increased when it is combined with Lapatinib.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Lapatinib.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Lapatinib.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Lapatinib.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Lapatinib.
Lapatinib Ditosylate Toxicity & Overdose RiskOne patient who took 3,000 mg of lapatinib for 10 days had severe diarrhea and vomiting on the last day of treatment.
image of a doctor in a lab doing drug, clinical research

Lapatinib Ditosylate Novel Uses: Which Conditions Have a Clinical Trial Featuring Lapatinib Ditosylate?

78 active trials are currently in progress to assess the efficacy of Lapatinib Ditosylate in providing Advance Directives, Metastatic Breast Cancer and Breast related treatments.
Condition
Clinical Trials
Trial Phases
Postmenopause
8 Actively Recruiting
Phase 2, Not Applicable, Phase 1
Breast
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2

Lapatinib Ditosylate Reviews: What are patients saying about Lapatinib Ditosylate?

4Patient Review
3/11/2011
Lapatinib Ditosylate for HER2 Positive Breast Cancer
Despite some initial setbacks with side effects, this drug was eventually able to be reduced to an effective dose. In combination with other drugs, it successfully shrank a mass to the point where it was no longer visible on an MRI within three months.
3.3Patient Review
4/9/2010
Lapatinib Ditosylate for HER2 Positive Breast Cancer
I took this in conjunction with Capacitabine. The first course of Lapatinib for four weeks and Capacitabine for three weeks showed significant improvement, pain reduction, and visible decrease in symptoms. However, when I started the second round, sudden bubbles appeared all over my body--particularly on my hands and feet--along with edema. This led my doctor to stop the medication.
2.3Patient Review
11/2/2010
Lapatinib Ditosylate for HER2 Positive Breast Cancer
I had diarrhea every day while taking this medication. It was given to me as part of a clinical trial for women with HER2+ node positive breast cancer (I was stage 3). I'm hopeful that it will help prevent recurrence.
1.7Patient Review
3/24/2014
Lapatinib Ditosylate for Hormone Receptor Positive, HER2 Positive Metastatic Breast Cancer
My face and scalp started developing painful acne-like pimples within two days of taking this medication. Unfortunately, it did not work for me as intended; I had to resort to traditional chemotherapy eventually.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about lapatinib ditosylate

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does lapatinib work in breast cancer?

"Tykerb is a HER2 inhibitor targeted therapy that works against HER2-positive breast cancers by blocking certain proteins that can cause uncontrolled cell growth."

Answered by AI

What is lapatinib used for?

"Lapatinib is used in conjunction with capecitabine to treat a certain type of advanced breast cancer in patients who have already received treatment with other chemotherapy drugs."

Answered by AI

What kind of inhibitor is lapatinib?

"Lapatinib is a drug taken orally that targets two proteins, epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor-2 (HER2). These proteins are often overexpressed in cancer."

Answered by AI

Is lapatinib FDA approved?

"The US Food and Drug Administration has approved Tykerb, in combination with capecitabine, as a treatment for patients with advanced or metastatic breast cancer who have overexpressed HER2 and have received prior therapies including an anthracycline, a taxane, and trastuzumab."

Answered by AI

Clinical Trials for Lapatinib Ditosylate

Have you considered Lapatinib Ditosylate clinical trials? We made a collection of clinical trials featuring Lapatinib Ditosylate, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top